TimothyKuzelMDFACP

Cutaneous Lymphoma, Genitourinary Oncology, Hematologic Oncology, Melanoma

Clinical Professor of Medicine Northwestern University Distinguished Physician, St George corp Associate Director Clinical Research Network, Robert H Lurie Comprehensive Cancer Center Northwestern University Oncology Service Line Lead, South Region

Join to view full profile

Dr. Kuzel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kuzel's full profile

Already have an account?

Office
15300 West Ave
Robert H Lurie Comp Ca Ctr
Orland Park, IL 60462
Phone+1 708-226-2513

Fax+1 312-942-3192

Summary

I am the Samuel G Taylor III Professor of Oncology, and the Chief of the Division of Hematology/Oncology and Cell Therapy at Rush University since June 2016. Prior to that I spent 26 years as a Professor of Medicine and Dermatology in the Division of Hematology/Oncology at Northwestern University, Feinberg School of Medicine. I have focused my career on the design and execution of clinical trials with a specific focus on experimental therapeutics, especially phase I and phase II therapeutics rationally designed to exploit molecular and/or protein alterations within tumor cells and immunotherapeutic approaches/agents. Agents utilized have included chemotherapy drugs, targeted agents, cytokines, vaccines, and other novel immunotherapeutics. I have been a Co-PI on a SPORE in Prostate Cancer at Northwestern focused on immunomodulation to reverse resistance to oral novel anti-androgen therapies (the grant is in NCE thru Aug 2021). I have also had Prostate Cancer Foundation and NIH funding for translational agent development. I also worked in the area of shared decision making and identification of adverse events associated with drug therapy of cancer. I have served on a number of NCI site visit teams as a reviewer for Program Projects for 1) Immunotherapy in renal cell Ca, 2) Melanoma with dendritic cell-based immunotherapy approaches, and 3) Cellular immunotherapy, as well as 4) Community based NCI centers (NCOROP), and Novel Statistical Clinical Programs. In addition, I participated on several NCCN guidelines committees including Kidney/Testis and Bladder and Prostate at various times. I serve on multiple Data Monitoring Committees of phase II and III global check point inhibitor clinical trials.

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1987 - 1990
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1984 - 1987
University of Michigan Medical SchoolClass of 1984
University of MichiganBA, Biomedical Sciences, Cum Laude, 1978 - 1981
University of MichiganB.S., Biomedical Sciences, 1981

Certifications & Licensure

IL State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Chicago Magazine: Top Doctors Castle Connolly, 2008, 2010, 2012, 2014, 2016, 2018, 2020
America's Top Doctors Castle Connolly, 2008-2017
America's Top Doctors for Cancer Castle Connolly, 2007-2017
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Chicago’s Best Doctors 2005
Fellow (FACP) American College of Physicians, 2004
Fellowship American College of Physicians, 2004
Teaching Attending of the Year, Division of Hematology/ Oncology Feinberg School of Medicine, 2001
Clinical Oncology Career Development Award American Cancer Society, 1992
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1991 Oct 01
Completed
Phase 2
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Start of enrollment: 1999 May 20
Completed
Phase 2
Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1998 May 01
Terminated
Phase 2
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome Start of enrollment: 1997 Apr 01
Terminated
Phase 2
Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome Start of enrollment: 2000 Jul 01
Completed
Phase 2
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer Start of enrollment: 2005 Nov 01
Completed
Early Phase 1
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer Start of enrollment: 2005 Apr 01
Completed
Early Phase 1
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma Start of enrollment: 2005 Jan 30
Completed
Phase 1, Phase 2
Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome Start of enrollment: 2006 Aug 28
Terminated
Phase 1
Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma Start of enrollment: 2008 Jun 01
Unknown status
Phase 1
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2008 Jul 01
Terminated
Not Applicable
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
Completed
Phase 1, Phase 2
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Start of enrollment: 2010 Sep 17
Completed
Phase 2
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
Completed
Phase 1, Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2012 Sep 01
Active, not recruiting
Phase 1, Phase 2
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma Start of enrollment: 2013 Mar 22
Terminated
Phase 1
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
Completed
Phase 2
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
Completed
Phase 2
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Low-moderate Intensity Pedaling During Immunotherapy Administration Start of enrollment: 2020 Jan 31
Withdrawn
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Francine M Foss, Youn H Kim, H Miles Prince, Oleg E Akilov, Christiane Querfeld
Journal of Clinical Oncology. 2024-12-19
2 citations
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang
Clinical Cancer Research. 2024-10-01
Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.
Malia E Leifheit, Gunnar Johnson, Timothy M Kuzel, Jeffrey R Schneider, Edward Barker
International Journal of Molecular Sciences. 2024-08-30

Journal Articles

Type 2 Innate Lymphoid Cells Impede IL-33–Mediated Tumor Suppression
Timothy M Kuzel, Bin Zhang, The Journal of Immunology
The Present and Future Cardiovascular Medicine and Society the Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (Or Onco-Cardiology) and Call to Action
Agne Paner, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Tochi M Okwuosa, Nicole Prabhu, Kim A Williams, ScienceDirect
The efficacy of lenvatanib and everolimus in Chromophobe-type non-Clear Cell Renal Cell Cancer: A case report and Literature review
Schwartz C, Pfanzelter N, Kuzel TM, Clin Genitourin Cancer, 1/25/2017
A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanoma: A trial of the ECOG-ACRIN Cancer Res...
Kevin Kalinsky, Sandra Lee, KristaRubin, Donald P. Lawrence, Anthony J. Iafrarte, Darell R. Borger, Kim A. Margolin, Mario M. Leitao, Jr, Ahmad A. Tarhini, Henry B. Ko..., Cancer, 1/23/2017
Exogenous IL-33 restores dendritic cell activation and maturation in established cancer
Dominguez D, Ye C, Geng Z, Chen S, Fan J, Qin L, Long A, Wang A, Zhang Z, Zhang Y, Fand D, Kuzel TM, Bin Zhang, Journal of Immunology, 1/1/2017
Exogenous IL-33 overcomes T cell tolerance in acute myeloid leukemia
Lei Qin, Donye Dominguez, Siqi Chen, Jie Fan, Alan Long, Minghui Zhang, Deyu Fang, Timothy M. Kuzel, Bin Zhang, OncoTarget, 1/10/2016
Durable responses with maintenance dose-sparing regimens of romidepsin in CTCL
Martinez-Escala ME, Kuzel TM, Kaplan JB, Petrich A, Nardone B, Rosen ST, Guitart J, JAMA Oncology, 1/7/2016
National Evaluation of Hospital Performance on the New Commission on Cancer Melanoma Quality Measures
Minami C,... Kuzel TM,…Bilimoria, K, Annals of Surgical Oncology, 1/1/2016
Novel use of targeted therapy via a PARP-inhibition in a rare form of papillary renal cell carcinoma: A case report and literature review
Olson D, Ghalia, S, Yang X, Martone B, Kuzel TM, Clinical Genitourinary Cancer, 1/1/2016
The effects of the order of multiple imputation in subset analysis examining the association between body mass index (BMI) and transrectal ultrasound prostate weight
Helenowski, I.B., Demirtas, H., Doll, J.A., Jovanovic, B.D., Gurley, M.J., Trapp, L.P., Kuzel, T.M., Convergent Science Physical Oncology, 1/1/2016
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond ProgressionA Subgroup Analysis of a Randomized Clinical Trial
Saby George, MD; Robert J. Motzer, MD; Hans J. Hammers, MD, PhD; Bruce G. Redman, DO; Timothy M. Kuzel, MD; Scott S. Tykodi, MD, PhD; Elizabeth R. Plimack, MD, MS; Joe..., JAMA Oncol, 1/1/2016
Advancements in unresectable melanoma: a multidisciplinary perspective
Mary-Kate Malecek, MD, June K. Robinson, MD, Karl Bilmoria, MD, Jennifer N. Choi, MD, Jaehyuk Choi, MD, PhD, Pedram Gerami, MD, Timothy M. Kuzel, MD, et al, Melanoma Management, 1/1/2016
Prostate Cancer Version 2/2014
Mohler JL, Kantoff PW, Armstrong AJ,…Kuzel TM, Lee RJ, Malcolm AW, et al, J Natl Compr Canc Network, 1/1/2014
High Incidence of Gastrointestinal Tract Disoders and Autoimmunity in Primary Cutaneous Marginal Zone B-cell Lymphomas
Guitart J, Deonizio J, Bloom T, Martine-Escala ME, Kuzel TM, Gerami P, Kwasny M , Rosen ST, JAMA Dermatol, 1/1/2014
Acute generalized exanthematous pustulosis in a patient receiving high-dose recombinant interleukin-2
Gunawardane ND, Vaghani SP, Kuzel TM, Cotliar JA, J Am Acad Dermatol, 1/1/2013
NCCN
Motzer RJ, Agarwal N, Beard C,…Kuzel TM,…Wilder RB, J Natl Compr Canc Netw, 1/1/2012
Kidney Cancer-Updated guidelines
Motzer RJ, Agarwal N, Beard C,…Kuzel TM....Wilder RB, J Natl Compr Canc Netw, 1/1/2011
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell Lymphoma
Querfeld C, Kuzel TM, Kim YH, Porcu P Duvic M, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye, M, Day JM, Rosen ST, Leuk Lymphoma, 1/1/2011
Cutaneous involvement with marginal zone lymphoma
Gerami P, Wickless SC, Querfeld C, Rosen ST, Kuzel TM, Guitart J, J Am Acad Dermatol, 1/1/2010
Eosinophilic Rash Secondary to Temsirolimus
Gandhi M, Kuzel T, Lacouture M, Clin Genitourin Cancer, 1/1/2009
Safety and Efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: An open label multicenter phase I/II study
Thompson JA, Kuzel T, Drucker BJ, Urba WJ, and Bukowski RM, Clinical Genitourinary Cancer, 1/1/2009
Effect of Sunitinib on renal cell carcinoma cutaneous metastasis
Liu SW, Guitart JG, Kuzel TM, Gandhi M, lacouture M, Int J Dermatol, 1/1/2009
NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer
Motzer RJ, Agarwal N, Beard C,…Kuzel TM, et al, J Natl Compr Canc Netw, 1/1/2009
NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer
Motzer RJ, Agarwal N, Beard C,…Kuzel TM, et al, J Natl Compr Canc Netw, 1/1/2009
A Comparison of the Renal Cell Carcinoma Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)
Rao D, Butt Z, Rosenbloom S, Robinson D, Von Roeen J, Kuzel TM, Cella D, J Pain and Symtom Manage, 1/1/2009
Join now to see all

Books/Book Chapters

Hematology: Basic Principles and Practice
Chapter: T-cell Lymphomas. Chapter 85
Page 1343 - 1380O'Connor OA, Bhagat G, Ganapathi KA, Kaplan J, Corradini P, Guitart J, Rosen ST and Kuzel TMEditors: Hoffman R, Benz EJ, Silberstein LE, Heslop H, Weitz JI, and Anastasi J.Elsevier/Saunders, Philadelphia, PAEdition 7th,2018
Cancer Consult: Expertise for Clinical Practice
Chapter: Management of Renal Cell Carcinoma. Chapter 95
MacVicar, Gary and Kuzel TMEditors: Markman M and Abutalib S.Wiley, Oxford, United Kingdom2014
Cancer Consult: Expertise for Clinical Practice
Chapter: Management of Bladder Cancer. Chapter 96
MacVicar, Gary and Kuzel TMEditors: Markman M and Abutalib S.Wiley, Oxford, United Kingdom2014
Merkel cell carcinoma.
Chapter: Chemotherapy in Merkel Cell Carcinoma. Chapter 10
Page 135 - 140Roy, Rupali and Kuzel TMEditors: Alam M, Bordeaux J, Yu S.Springer, New York, NY2013
Hematology: Basic Principles and Practice
Chapter: T-cell Lymphomas. Chapter 84
Page 1267 - 1302O’connor OA, Marchi E, Ghagat G, Corradini P, Guitart J, Rosen ST and Kuzel TMEditors: Hoffman R, Benz EJ, Silberstein LE, Heslop H, Weitz JI, and Anastasi J.Elsevier/Saunders, Philadelphia, PAEdition 6th,2013
Cutaneous lymphoma: diagnosis and treatment
Chapter: Adult T-cell leukemia/lymphoma. Chapter 8
Page 117 - 124Galvin JP, Kuzel TMEditors: Hall, JC and Hall, BJ.People's Medical Pub. House-USA, Shelton, CT2012
Conn’s Current Therapy 2009
Chapter: Cutaneous T-cell lymphoma (Mycosis fungoides and Sezary’s syndrome).
Querfeld C, Kuzel TM, Rosen STEditors: Robert E. Rakel and Edward Bope.Elsevier/ Saunders, Philadelphia, PAEdition 61st,2009
Hematology: Basic Principles and Practice
Chapter: Cutaneous T-cell Lymphoma
Page 1359 - 1376Kuzel TM, Guitart J, and Rosen STEditors: Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P, and Heslop H.Elsevier/Churchill-Livingstone, Philadelphia, PAEdition 5th,2009
Clinical Malignant Hematology
Chapter: Treatment Approach to Cutaneous Lymphomas. Chapter 59.
Page 601 - 612Querfeld C, Kuzel TM, Guitart J, and Rosen, STEditors: Sekeres MA, Kalaycio ME and Bolwell BJ.McGraw-Hill, New York, NYEdition 1st,2007
Conn’s Current Therapy 2006
Chapter: Cutaneous T-cell lymphoma (Mycosis Fungoides and Sezary’s syndrome)
Page 955 - 962Querfeld C, Rosen ST, Guitart J, Kuzel TMEditors: Robert E. Rakel, MD and Edward T. Bope, MD.Elsevier/Saunders, Philadelphia, PAEdition 58th,2006
Conn’s Current Therapy 2005
Chapter: Cutaneous T-cell lymphoma (Mycosis Fungoides and Sezary’s syndrome). Section 13, Chapter 198.
Page 902 - 906Querfeld C, Kuzel TM, Rosen STEditors: Robert E. Rakel, MD and Edward T. Bope, MD.Elsevier/Saunders, Philadelphia, PAEdition 57th,2005
Cytokines and Cancer
Chapter: Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Chapter11.
Page 263 - 288Eklund JW and Kuzel TMEditors: Platanias L and Carson W.Spring Science and Business Media, Inc., New York, NY2005
Hematology: Basic Principles and Practice
Chapter: Cutaneous T-cell Lymphomas. Chapter 81
Page 1467 - 1486Kuzel TM, Guitart J, and Rosen STEditors: Hoffman R, Benz EJ, Shattil SJ, Fuire B, Cohen HJ, Silberstein LE, and McGlave P.Elsevier/Churchill-Livingstone, Philadelphia, PAEdition 4th,2005
Oncologic Therapies.
Chapter: Cutaneous T-cell Lymphomas. Chap 21.
Page 283 - 294Kuzel TM, Guitart J, and Rosen STEditors: Vokes EE, and Golomb H.Springer-Verlag, Heidelburg, GermanyEdition 2nd,2003
Dermatologic Therapy.
Chapter: Systemic Chemotherapy for the Treatment of Mycosis Fungoides and the Sezary syndrome
Page 353 - 359Kuzel TMEditors: Wood GS and Tharp M.2003
Cutaneous Lymphoma-Hematology/Oncology Clinics of North America.
Chapter: Cytokine Therapies for CTCL: Interferons, Interluekin-12, and Interleukin-2
Page 1435 - 1448Rook A, Kuzel TM, Olsen EW. B. Saunders, An imprint of Elsevier Science, Inc2003
Cutaneous Lymphoma-Hematology/Oncology Clinics of North America.
Chapter: Novel Agents for Cutaneous T-cell Lymphoma
Page 1459 - 1466Foss F, Kuzel TM, Junghans RW. B. Saunders, An imprint of Elsevier Science, Inc.2003
Cutaneous Lymphoma-Hematology/Oncology Clinics of North America.
Chapter: High Dose therapy and bone marrow transplantation in CTCL
Page 1475 - 1484Oyama Y, Guitart J, Kuzel TM, Burt RK and Rosen STW. B. Saunders, An imprint of Elsevier Science, Inc.2003
Outline of Oncology Therapeutics.
Chapter: DAB389IL-2
Kuzel TM and Samuelson EEditors: Ratain MJ and Tempero M.W.B. Saunders, Philadelphia, PA2001
HIV and HTLV-1 Associated Malignancies. Sparano J. Cancer Treatment and Research Series
Chapter: HTLV-1 Associated Leukemia/Lymphoma. Chapter 3.
Page 75 - 88Siegel R, Gartenhaus R, and Kuzel TMKluwer Academic Publishers, Norwell, MA2001
Robert H. Lurie Cancer Center Handbook of Hematology/Oncology,
Chapter: Urologic Tumors. Chapter 5
Page 82 - 107Campbell, S, Kozlowski JM, Kuzel TM, Nadler REditors: Rosen ST and Kuzel TM.PRR, Inc., Melville, NY2001
Strategies in Adjuvant Therapy
Chapter: Malignant Lymphomas
Page 41 - 66Kuzel TM, Traynor A, and Rosen STEditors: Kirkwood JM.Martin Dunitz, Ltd., London, England2000
Oncologic Therapies.
Chapter: Cutaneous T-cell Lymphomas
Page 419 - 438Kuzel TM, Guitart J, and Rosen STEditors: Vokes EE, and Golomb H.Springer-Verlag, Heidelburg, GermanyEdition 1st,1999
Hematology: Basic Principles and Practice
Chapter: Cutaneous T-cell Lymphomas
Page 1372 - 1388Kuzel TM, Guitart J, and Rosen STEditors: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, and McGlave P.Churchill-Livingstone, New York, NYEdition 3rd,1999
Cancer Treatment and Research--Diagnostic and Therapeutic Advances in Hematologic Malignancies
Chapter: Novel treatment approaches for Cutaneous T-cell Lymphoma, Chapter 9
Page 227 - 240Foss FM and Kuzel TMEditors: Martin S Tallman and Leo I Gordon.Kluwer Academic Publishers, Norwell, MA1999
Join now to see all

Abstracts/Posters

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-HodgkinÍs Lymphoma
Timothy M. Kuzel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of use of Phosphodiesterase Type 5 Inhibitors (PDE5-I) after Radical Prostatectomy (RP) on Biochemical Recurrence-free (BCRF) and Overall Survival (OS): A Retro...
Arden B. Roston, Irene B. Helenowski, William Catalona, Robin Leikin, Michael Gurley, Luke Trapp, Borko Jovanovic, Timothy M. Kuzel, J Clin Oncol; Proc of GU ASCO, 1/1/2017
Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell...
Sumanta Pal, Robert J Motzer, Mayer Fishman, Raymond McDermott, Jose Passos Coelho, Evgeniy Kopyltsov, Xavier Garcia del Muro Solans, Jesús Garcia Donas, Ramazan Yildi..., J Clin Oncol; Proc of GU ASCO, 1/1/2017
NCI 8628 - A Randomized Phase II Study of Ziv-aflibercept (Z) and High Dose Interleukin-2 (IL-2) or IL-2 alone for Inoperable Stage III or IV Melanoma.
Ahmad A Tarhini, Paul Frankel, Christopher Ruel, Marc S Ernstoff, Timothy M Kuzel, Theodore F Logan, Nikhil I Khushalani, Hussein A Tawbi, Kim A Margolin, Sanjay Awast..., Proceedings of AACR, 1/1/2017
TGF-beta insensitive PSMA-specific CD8+ T cells derived from metastatic castration resistant prostate cancer (MCRPC) patients enhance the tumor killing ability.
Qiang Zhang, Timothy Kuzel, Brian Helfand, Ximing J. Yang, Weijun Qin, Chung Lee, Benedito Carneiro, Francis J. Giles, Proceedings of AACR, 1/1/2017
Comparing association of trans rectal ultrasound prostate weight with actual prostate weight obtained after radical prostatectomy after adjustment for other prognostic...
Helenowski, I.B., Jovanovic, B.D., Gurley, M.J., Leikin, R.G., Catalona W.J., Rosten, A.B., Kuzel, T.M., Proceedings of the American Physical Society, New Orleans, LA, 1/1/2017
Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o...
Julia Scarisbrick, Steven M. Horwitz, Reinhard Dummer, Madeleine Duvic, Youn H. Kim, Jan Walewski, Sean Whittaker, Pietro Quaglino, Pier Luigi Zinzani, Pascal Wolter, ..., Proceedings of the American Society of Hematology, Atlanta, GA, 1/1/2017
Suppression of human prostate cancer (CaP) by adoptive transfer of patient-derivedPSMA-specific, TGF-beta-insensitive CD8+ T cells.
Qiang Zhang, Timothy Kuzel, Brian Helfand, Ximing J. Yang, Weijun Qin, Chung Lee, Benedito Carneiro, Francis J. Giles, Proceedings of the AUA, 1/1/2017
A phase 1/2 study combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy-and immunotherapy-naïve patients with progressive metastatic castration...
Daniel Costin Danila, Timothy Kuzel, Jeremy Paul Cetnar, Dana E. Rathkopf, Michael J. Morris, Joshi J. Alumkal, Alex Butler, Tracy Curley, Melanie Hullings, Joshua R. ..., J Clin Oncol; Proc of ASCO, 1/1/2016
Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.
David F. McDermott, Robert J. Motzer, Michael B. Atkins, Elizabeth R. Plimack, Mario Sznol, Saby George, Charles G. Drake, Brian I. Rini, Toni K. Choueiri, Timothy Kuz..., J Clin Oncol; Proc of ASCO, 1/1/2016
A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer R...
Kevin Kalinsky, Sandra J. Lee, Krista M. Rubin, Donald P. Lawrence, A. John Iafrate, Darrell R. Borger, Kim Allyson Margolin, Mario M. Leitao, Henry B. Koon, Ahmad A. ..., J Clin Oncol; Proc of ASCO, 1/1/2016
Use of statins and the risk of prostate cancer biochemical recurrence in men treated with radical prostatectomy.
Luke Trapp, Irene B. Helenowski, Michael Gurley, Robin Leikin, William Catalona, Borko Jovanovic, Timothy Kuzel, J Clin Oncol; Proc of ASCO, 1/1/2016
ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features.
Naomi B. Haas, Maneka Puligandla, David F. McDermott, Janice P. Dutcher, Judith Manola, Michael Pins, Michael Anthony Carducci, Jacqueline Vuky, Bradley Curtis Carthon..., J Clin Oncol; Proc of ASCO, 1/1/2016
E7777 Demonstrated Safety in Persistent or Recurrent Cutaneous T-Cell Lymphoma.
Madeleine Duvic, MD, Timothy M. Kuzel, MD, Nam H. Dang, MD, PhD, Miles Prince, MD, FRACP, FRCPS, Tatyana Feldman, MD, Francine M. Foss, MD,Min Ren, PhD, Kalgi Mody, MD..., Proc of World Congress of Cutaneous Lymphomas, 1/1/2016
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
A. Ribas, M. Butler, L. Lutzky, DP Lawrence, ...T. Kuzel, ...M. S. Gordon, Proc of ASCO, 1/1/2015
Updated survival results from a randomized, dose-ranging phase II study of nivolumab in metastatic renal cell carcinoma.
ER Plimack, HJ Hammers, BI Rini....T. Kuzel, MR Harrison,…R. Motzer, Proc of ASCO, 1/1/2015
Dose analysis of ASSURE (E2805); Adjuvant sorafenib ro sunitinib for unfavorable renal carcinoma, and ECOG – ACRIN led NCTN phase 3 trial.
Naomi Haas, ....A. S. Jewett, Bob Coomes, Surena F. Matin, Timothy Kuzel, Wade Jeffers Sexton, Yu-Ning Wong, Toni K. Choueiri, Roberto Pili, ... R.s. DiPaola, Proc of ASCO, 1/1/2015
A novel method of expansion for low numbers of human CD8+ T cells in metastatic castration resistant prostate cancer (mCRPC) patients in clinic.
Qiang Zhang, Brian Helfand, AnnLeFever, Chung Lee, Timothy Kuzel, Proc of 105th (AACR) Annual Meeting; Cancer Research Late breaking, 1/1/2014
Human prostate cancer invasion is suppressed by 5-Aza-2'-deoxycytidine which can inhibit the TGF-beta induced DNA methyltransferase (DNMT).
Qiang Zhang, Brian Helfand, Thomas Jang, Xiao Lin, Timothy Kuzel, Chung Lee, Proc of 105th AACR Annual Meeting, 1/1/2014
TGF-beta insensitivity promotes the proliferation of human CD8+ T cells in metastatic castration resistant prostate cancer (MCRPC) patients.
Qiang Zhang, Brian Helfand, Ann LeFever, Chung Lee, Timothy Kuzel, Proc of AACR, 1/1/2014
Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.
Atkins MB, Kudchadkar RR, Sznol M, McDermott DF, Lotem M, Schachter J, Wolchok JD, Urba WJ, Kuzel T, Schuchter LM, Slingluff CL, Ernstoff, MS, Fay JW, Friedlander PA, ..., Proc of ASCO, 1/1/2014
Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel T, et al, Proc of ASCO, 1/1/2014
A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL).
Madeleine Duvic, Timothy M Kuzel, Nam H. Dang, Miles Prince, Tatyana Feldman, Francine M. Foss, Matthew Guo, Lone Harild Ottesen, Chean Eng Ooi and Youn H Kim, Proc of ASH, 1/1/2014
Phase I/II Clinical trial of ALT-801, a T-Cell Receptor/IL-2 Fusion Protein, plus Gemcitabine and Cisplatin in Urothelial Cancer.
Fishman MN, GadjenbergJ, Kuzel T, Mahipal A, Rosser CJ, Landau D, Gupta S, Vaena DA, Agarwals SS, ....Wong HC, Proc GU ASCO, 1/1/2013
Correlation of pathologic findings after brief neoadjuvant sorafenib with results of dynamic contrast enhanced and diffusion-weighted magnetic resonance imaging, in pa...
MacVicar GR, Miller F, Rustogi R, Chen Z, Martone BK, Kuzel T, Proc GU ASCO, 1/1/2013
Join now to see all

Lectures

Updated Analyses of the International, Open-label, Randomized, Phase 3 ALCANZA Study: Longer-term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate o...
London, United Kingdom - 1/13/2017
Immunotherapy of Cancer
1/1/2012
A phase 2 mutli-center, randomized, open-label study of two dose levels of IMO-2055 in Patients with metastatic or recurrent Renal Cell Carcinoma.
1/1/2009
Sezary syndrome. Published in Proceedings of SH/EAHP Workshop. Progress in T-cell and NK cell Malignancies.
Houston, TX - 1/20/2005
Phase I trial demonstrates the safety and efficacy of targretin Topical gel, a novel RXR-selective retinoid analogue in the treatment of mycosis fungoides.
1/1/1997
Correlation of Clinical responses with Morphologic and Immunologic Characteristics in Cutaneous T-Cell Lymphoma patients Treated with Interferon Alfa-2a.
1/1/1989
Ligand Toxin Fusion Toxins are a new class of Therapies with Anti-Tumor Activity in Non-Hodgkin's Lymphoma.
Join now to see all

Other

The use of Gemcitabine in metastatic urothelial transitional cell cancer
Kuzel TM and Stadler WM, Lilly Monograph
1/1/1996
Book Review of --Atkins MB and Mier JW. Therapeutic Applications of Interleukin-2.
Kuzel TM, Doody's Health Sciences Book Review Annual
1/1/1993
Interferons: Basic Principles and Clinical Applications.
Kuzel TM. Book Review of --Estrov Z, Kurzock R, and Talpaz M, Doody's Health Sciences Book Review Annual
1/1/1993

Press Mentions

Combination Treatment Improves Survival in Advanced Prostate Cancer with Genetic MutationsSeptember 6th, 2024
Rush Earns ASCO QOPI Certification for High-Quality Cancer CareSeptember 5th, 2019
Personalized Vaccine Helps Patients Fight Ovarian CancerApril 12th, 2018
Join now to see all